Euronext Amsterdam

Vivoryon Therapeutics N.V.

HealthcareLEI 3912004AMB0KGZXZYJ15Filings at the AFM Nederlands

At a glance

Most recent filing on September 29, 2026 — a grant by Irsfeld M. on Sep 29, 2026.

Over the past 12 months: 2 open-market purchases and 0 open-market sales.

We hold 52 visible filings, going back to November 30, 2020.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 52 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings for this company, out of 52. Reading the whole list, and the full filer page behind every line, is part of the subscription. So are the insider score for this company, the price beside each line, the price history with every buy marked on it, any moments when several insiders bought within ninety days, and following this company. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Some of these filings come from the AFM register of board members and supervisory directors (art. 5:48 Wft). The AFM board-member register gives no transaction type; we derive it from the number of shares and the price.

Irsfeld M. Board or supervisory board member
116,000 sharesGrant
TradedSep 29, 2026FiledSep 29, 2026
Irsfeld M. CFO
60,000 sharesGrant
TradedApr 17, 2026FiledApr 22, 2026
Weber F. Board or supervisory board member
150,000 sharesGrant
TradedApr 17, 2026FiledApr 17, 2026
Neugebauer J. Board or supervisory board member
150,000 sharesGrant
TradedApr 17, 2026FiledApr 17, 2026
Schaeffer M. Board or supervisory board member
150,000 sharesGrant
TradedApr 17, 2026FiledApr 17, 2026

The insider score is a rank of the most recent scored buy, not a forecast. How it is calculated is in the methodology. Source: the Dutch AFM register (MAR art. 19).